GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (NAS:SYRS) » Definitions » Beneish M-Score

SYRS (Syros Pharmaceuticals) Beneish M-Score : -7.91 (As of Dec. 12, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -7.91 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Syros Pharmaceuticals's Beneish M-Score or its related term are showing as below:

SYRS' s Beneish M-Score Range Over the Past 10 Years
Min: -7.91   Med: -2.65   Max: 3.33
Current: -7.91

During the past 10 years, the highest Beneish M-Score of Syros Pharmaceuticals was 3.33. The lowest was -7.91. And the median was -2.65.


Syros Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Syros Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals Beneish M-Score Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.58 1.94 -0.89 -3.36 -4.48

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.35 -4.48 -4.84 -4.39 -7.91

Competitive Comparison of Syros Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Syros Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Beneish M-Score falls into.



Syros Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Syros Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0+0.528 * 1+0.404 * 1.1656+0.892 * 0.0439+0.115 * 1.619
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 17.8398+4.679 * -0.142726-0.327 * 1.7207
=-7.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0.386 = $0.39 Mil.
Gross Profit was 0 + 0 + 0 + 0.386 = $0.39 Mil.
Total Current Assets was $63.93 Mil.
Total Assets was $85.00 Mil.
Property, Plant and Equipment(Net PPE) was $17.58 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.34 Mil.
Selling, General, & Admin. Expense(SGA) was $23.27 Mil.
Total Current Liabilities was $28.39 Mil.
Long-Term Debt & Capital Lease Obligation was $57.64 Mil.
Net Income was -6.396 + -23.327 + -3.708 + -64.384 = $-97.82 Mil.
Non Operating Income was 20.305 + 4.386 + 26.974 + -37.333 = $14.33 Mil.
Cash Flow from Operations was -20.689 + -29.667 + -31.098 + -18.562 = $-100.02 Mil.
Total Receivables was $1.67 Mil.
Revenue was 3.762 + 2.833 + 2.954 + -0.754 = $8.80 Mil.
Gross Profit was 3.762 + 2.833 + 2.954 + -0.754 = $8.80 Mil.
Total Current Assets was $122.52 Mil.
Total Assets was $147.80 Mil.
Property, Plant and Equipment(Net PPE) was $20.08 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.61 Mil.
Selling, General, & Admin. Expense(SGA) was $29.72 Mil.
Total Current Liabilities was $28.39 Mil.
Long-Term Debt & Capital Lease Obligation was $58.55 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.386) / (1.665 / 8.795)
=0 / 0.189312
=0

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(8.795 / 8.795) / (0.386 / 0.386)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (63.931 + 17.579) / 84.995) / (1 - (122.515 + 20.081) / 147.795)
=0.041002 / 0.035177
=1.1656

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.386 / 8.795
=0.0439

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.605 / (2.605 + 20.081)) / (1.342 / (1.342 + 17.579))
=0.114829 / 0.070926
=1.619

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(23.272 / 0.386) / (29.723 / 8.795)
=60.290155 / 3.379534
=17.8398

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((57.642 + 28.392) / 84.995) / ((58.55 + 28.394) / 147.795)
=1.012224 / 0.588274
=1.7207

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-97.815 - 14.332 - -100.016) / 84.995
=-0.142726

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Syros Pharmaceuticals has a M-score of -7.91 suggests that the company is unlikely to be a manipulator.


Syros Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Syros Pharmaceuticals Business Description

Traded in Other Exchanges
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
Executives
Nancy A Simonian director, 10 percent owner, officer: President & CEO C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Gerald E Quirk officer: Chief Legal Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David Roth officer: Chief Medical Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jason Haas officer: Chief Financial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Kristin Stephens officer: Chief Development Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley officer: Chief Commercial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Eric R Olson officer: Chief Scientific Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson director ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Richard A Young director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn officer: Chief Business Officer C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421

Syros Pharmaceuticals Headlines

From GuruFocus